Loading...

“CME/CE NetWorkShops™: Issues and Challenges in Your Hemophilia Treatment Center”

Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, registered nurses, physical therapists, social workers, and other specialists of the hemophilia treatment center (HTC) team, as well as clinicians interested in the treatment and management of patients with hemophilia.

Statement of Need/Program Overview
Hemophilia is the most common and severe inherited bleeding disorder recognized in humans and comprises the largest proportion of patients managed in most bleeding disorder clinics and HTCs. For many practicing clinicians, there is neither time nor opportunity to attend the major national and international society meetings to gain insights into a range of clinical challenges and patient management issues frequently encountered in the HTC setting.

With the CME/CE NetWorkShops™ series, however, these meetings can be brought to busy clinicians in the form of webcasts and organized group workshops at or near HTCs. Healthcare professionals are now able to view, analyze, and discuss key meeting findings with recognized hemophilia experts while gaining ideas on how to apply new learning to their own clinical practice.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Discuss selected scientific posters, abstracts, and published articles on topical issues in hemophilia, including burden of illness, morbidity, and dosing strategies
  • Compare treatment strategies, including immune tolerance induction, for patients with hemophilia A and inhibitors
  • Describe bleeding phenotype and characteristics of anti-factor VIII autoantibodies in acquired hemophilia
  • Develop management strategies to minimize joint damage in patients with severe hemophilia A
  • Provide appropriate care and counsel for hemophilia patients and their families
Planning Faculty
Miguel A. Escobar, MD
Associate Professor
Department of Pediatrics and Internal Medicine
Division of Hematology
University of Texas Health Science Center at Houston
University of Texas MD Anderson Cancer Center
Medical Director, Gulf States Hemophilia and Thrombophilia Center
University of Texas—Houston Medical School
Houston, Texas

Craig Kessler, MD, MACP
Professor of Medicine and Pathology
Chief of the Division of Coagulation
Director of the Coagulation Laboratory
Georgetown University Medical Center
Washington, DC

Thomas Loew, MD
Division Director
Professor of Clinical Child Health
University of Missouri Health System
Columbia, Missouri

Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan

Doris Quon, MD, PhD
Medical Director
Orthopaedic Hemophilia Treatment Center
Orthopaedic Institute for Children
Los Angeles, California

Mark T. Reding, MD
Associate Professor of Medicine
Hematology, Oncology and Transplantation Division
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical School
Minneapolis, Minnesota

Presenting Faculty
Miguel A. Escobar, MD
Associate Professor
Department of Pediatrics and Internal Medicine
Division of Hematology
University of Texas Health Science Center at Houston
University of Texas MD Anderson Cancer Center
Medical Director, Gulf States Hemophilia and Thrombophilia Center
University of Texas—Houston Medical School
Houston, Texas

Craig Kessler, MD, MACP
Professor of Medicine and Pathology
Chief of the Division of Coagulation
Director of the Coagulation Laboratory
Georgetown University Medical Center
Washington, DC

Thomas Loew, MD
Division Director
Professor of Clinical Child Health
University of Missouri Health System
Columbia, Missouri

Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan

Doris Quon, MD, PhD
Medical Director
Orthopaedic Hemophilia Treatment Center
Orthopaedic Institute for Children
Los Angeles, California

Mark T. Reding, MD
Associate Professor of Medicine
Hematology, Oncology and Transplantation Division
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical School
Minneapolis, Minnesota

Program Agenda
40-minute live webcast presentation
20-minute interactive question-and-answer session

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Fee Information
There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks
(if applicable).

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Miguel A. Escobar, MD Consulting Fees: Baxter, Biogen Idec, Novo Nordisk, Pfizer; Contracted Research: Baxter, Bayer, Biogen Idec, CSL Behring, Novo Nordisk, Octapharma, Pfizer
Craig Kessler, MD, MACP Consulting Fees: Baxter, Bayer HealthCare, Biogen Idec, Chugai Pharma USA, Grifols, Novo Nordisk, Pfizer, Octapharma; Contracted Research: Baxter, Bayer HealthCare, Novo Nordisk, Octapharma
Thomas Loew, MD Contracted Research: Eli Lily and Company, Novartis
Steven W. Pipe, MD Consulting Fees: Baxter Bioscience, Biogen Idec, CSL Behring, Novo Nordisk, Pfizer
Doris Quon, MD, PhD Consulting Fees: Baxter, Biogen Idec, CSL Behring, Octapharma; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Baxter, Grifols, Novo Nordisk
Mark T. Reding, MD Consulting Fees: Baxter, Bayer HealthCare, Biogen Idec, Novo Nordisk; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Baxter; Contracted Research: Bayer HealthCare, Octapharma
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Managing Director; Jodi Andrews, Senior Director, Educational Programs, BS; Cassie Rametta, BA, Program Director; Kathleen Krafton, BA, Senior Medical Writer Have no real or apparent conflicts of interest to report.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by an educational grant from Novo Nordisk.

 
Supported by an educational grant from:
This activity is jointly sponsored/co-provided by:
All Rights Reserved. Use of this Web site is governed by the Terms of Use | Privacy Policy
©2014 Blood CME Center. All rights reserved.